Regadenoson

Drug Profile

Regadenoson

Alternative Names: CVT 3146; Lexiscan; Rapiscan

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CV Therapeutics
  • Developer Astellas Pharma; Gilead Sciences; National Jewish Health; Rapidscan Pharma Solutions
  • Class Imaging agents; Purines; Pyrazoles; Small molecules; Vasodilators
  • Mechanism of Action Adenosine A2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Coronary disorders
  • No development reported Pulmonary hypertension

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pulmonary-hypertension in USA (IV, Injection)
  • 05 Oct 2017 Rapidscan Pharma Solutions plans a phase II trial for Cardiovascular disorders (In children) in United Kingdom (EudraCT2015-000500-26 )
  • 14 Sep 2017 Astellas Pharma terminates a phase I trial in Pulmonary hypertension as the Principal Investigator left National Jewish Health in USA (IV) (NCT02220634)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top